

1 Randomized trial to compare acceptability of Magnesium Sulphate administration for  
2 preeclampsia and eclampsia: Springfusor pump versus standard of care

3

4 Authors

5 **Sam Ononge**<sup>1#</sup>, Annetee Nakimuli<sup>1</sup>, Josephat Byamugisha<sup>1</sup>, Moses Adroma<sup>1</sup>, Paul Kiondo<sup>1</sup>,  
6 Thomas Easterling<sup>2</sup>, Hillary Bracken<sup>3</sup>

7 <sup>1</sup>Department of Obstetrics and Gynaecology Makerere University College of Health Sciences

8 <sup>2</sup>University of Washington Seattle Washington USA

9 <sup>3</sup>Gynuity Health Projects NY USA

10 <sup>1</sup>Sam Ononge, Department of Obstetrics & Gynaecology, Makerere University College of Health  
11 Sciences, Kampala, Uganda

12 <sup>1</sup>Annetee Nakimuli, Department of Obstetrics & Gynaecology, Makerere University College of  
13 Health Sciences, Kampala, Uganda

14 <sup>1</sup>Josephat Byamugisha, Department of Obstetrics & Gynaecology, Makerere University College  
15 of Health Sciences, Kampala, Uganda

16 <sup>1</sup>Moses Adroma, Department of Obstetrics & Gynaecology, Makerere University College of  
17 Health Sciences, Kampala, Uganda

18 <sup>1</sup>Paul Kiondo, Department of Obstetrics & Gynaecology,  
19 Makerere University College of Health Sciences, Kampala, Uganda

20 <sup>2</sup>Thomas Easterling, University of Washington Seattle Washington USA

21 <sup>3</sup>Hillary Bracken, Gynuity Health Projects (GHP), 220 East 42nd Street, New York, NY 10017

22 USA

23

24

25 # Corresponding author: email [ononge2006@yahoo.com](mailto:ononge2006@yahoo.com)

26

## 27 **Abstract**

28 **Introduction:** In low-resource settings, magnesium sulphate ( $\text{MgSO}_4$ ) for preeclampsia is  
29 administered majorly through an injection into the gluteal muscles 4-hourly for 24 hours. The  
30 repeated injections are very painful and may lead to infection, abscess formation and reduced  
31 compliancy.

32 **Objective:** To determine the acceptability of Springfusor® pump for the administration of  
33 Magnesium Sulphate in preeclampsia and eclampsia.

34 **Design:** Randomized Open Label Clinical Trial

35 **Method:** Study was conducted at Kawempe National Referral Hospital. Eligible women had  
36 systolic blood pressure of  $\geq 140$ mmHg and or diastolic blood pressure  $> 90$ mmHg, proteinuria  
37  $\geq +1$ , and physician's decision to start on  $\text{MgSO}_4$ . Four-hundred-ninety-six participants were  
38 randomized to Springfusor® pump group or control (standard of care) administration of  $\text{MgSO}_4$ .  
39 Intervention group had loading dose (4gm of 50%  $\text{MgSO}_4$  intravenously over 20 minutes) and  
40 maintenance therapy (1gm of 50%  $\text{MgSO}_4$  intravenously per hour for 24 hours) administered  
41 using the Springfusor®. The control group received a loading dose of 4gm of 20%  $\text{MgSO}_4$  IV  
42 over 15-20 minutes, followed by 10gm of 50%  $\text{MgSO}_4$  intramuscular (5gm in each buttock) and  
43 maintenance dose of 5gm of 50%  $\text{MgSO}_4$  was administered IM every 4 hours for 24 hours. Both  
44 arms received the rest of the care for preeclampsia/eclampsia as per the hospital guidelines.  
45 Acceptability of method of administration was assessed using a Likert scale (1-5; 1 and 2:  
46 acceptable and 3-5: unacceptable). Pain at site of  $\text{MgSO}_4$  administration was assessed using  
47 Visual Analogue Scale 1-7, (1 minimal pain and 7 worst pain). Comparisons were assessed with  
48 X-square and Students' t-test.

49 **Results:** Baseline characteristics were similar in both arms. Intervention arm was; more  
50 acceptable than the standard of care arm, (94.9% vs70.3%;  $p<0.001$ ), had lower pain score  
51 ( $2.2\pm1.3$  vs.  $4.1\pm1.6$ ;  $p <0.001$ ) and fewer side effects. Maternal mortality was comparable  
52 between groups (0.8% in intervention arm vs 1.2% in the IM arm).

53 TRIAL REGISTRATION: Trial No PACTR201712002887266 (<https://pactr.samrc.ac.za/>)

54

55

56

## 57 **Introduction**

58 Preeclampsia is a multisystem disorder that presents with a raised blood pressure and proteinuria in  
59 pregnancy [1]. Globally, preeclampsia complicates approximately 2-8% of the pregnancies [2]. The  
60 presence of convulsions with preeclampsia indicates eclampsia. Preeclampsia and eclampsia are  
61 life-threatening for both the mother and the fetus[3], and they are among the leading causes of  
62 maternal deaths and disability worldwide, especially in the low resource setting[4]. The World  
63 Health Organization (WHO) estimates that, 16% of the maternal deaths in low resource settings  
64 are due to PE/E [5]. Magnesium Sulphate ( $MgSO_4$ ) is the drug of choice for prevention and  
65 treatment of eclampsia [5]. It is administered parenterally by intravenous (IV) and or  
66 intramuscular (IM) routes. The IV therapy is commonly administered following the Zuspan  
67 regimen that requires an initial loading dose of 4 gm of magnesium sulphate over 15-20  
68 minutes over 15-20 minutes (mins), followed by 1-2 gm hourly maintenance dose continuing for  
69 24 hours after the loading dose or the last eclamptic fit [6]. Zuspan regimen is best delivered by  
70 electronic infusion pumps. These electronic pumps are expensive and require electricity or  
71 battery to run, making them less appropriate in low resource settings. In many low resource  
72 settings,  $MgSO_4$  administration follows the Pritchard regimen. The regimen is particularly  
73 complex and requires both the IV and IM administration of  $MgSO_4$ . The loading dose of 4 gm is  
74 often delivered using an IV-push, in which clinicians slowly injects magnesium sulphate with a  
75 syringe over 15-20 mins. This is immediately followed by IM injection of 10 gm of magnesium  
76 sulphate into the gluteal muscles (5 gm on each buttock). The maintenance dose of 5 gm IM  
77 injection is administered every 4 hours for 24 hours. These repeated IM injections are painful,  
78 and can increase the risk of abscess development. Because of pain associated with the IM

79 injection, some providers do not administer maintenance therapy and patients too may  
80 discontinue the maintenance dose for the same reason. In addition, the Pritchard regimen  
81 requires different dilutions for IV and IM doses, and different doses for loading, and maintenance  
82 doses. This regimen requires a 20% dilution of magnesium sulphate for the IV loading dose,  
83 which necessitates the health providers to calculate the quantity of sterile water to add to the  
84 magnesium sulphate solution. In most settings, health providers do not encounter eclampsia very  
85 often; and when they do, trying to remember the complex regimen is challenging.

86 In low resources settings that cannot afford electronic infusion pumps, there was a need to test  
87 alternative devices that can effectively and safely deliver  $MgSO_4$  at cheaper cost, and  
88 acceptable to the patient and health provider. The Springfusor® pump and flow control tube  
89 (FCT) designed by Go Medical Industries Pty Ltd based in Australia [7], is a promising  
90 alternative to Pritchard method of administering  $MgSO_4$ , and is designed to simplify  
91 continuous IV infusions. The Springfusor pump does not require electricity and it is reusable.  
92 The Springfusor is powered by the potential energy stored within a spring at the heart of the  
93 device. The spring is compressed by the action of loading the Springfusor with the compatible  
94 syringe and FCT. The spring provides a constant force to the barrel of the loaded syringe. The  
95 flow rate is controlled by the FCT which offers consistent resistance to produce a steady flow.  
96 The FCT is a fine bore tube designed to provide a metered constant flow for IV infusion. FCTs  
97 has easy fitting to the patient's cannula. The FCT exist in a variety of flow rates which enables  
98 the user to attain the desired output for exact IV delivery needs. For this study we used two  
99 varieties of FCT; the loading dose and maintenance dose. While the Springfusor can be reused  
100 indefinitely on different patients, the FCT must be replaced after each use.

101 The Springfusor syringe infusion pump is a low cost, non-sterile, reusable pump that requires  
102 no external power source. It is simple to use and setup, and requires only minimal training to  
103 load and operate. It is lightweight, portable and therefore does not limit the mobility of the  
104 patient.

105 The Springfusor has been used to administer  $MgSO_4$  in the treatment of severe preeclampsia in  
106 India[8] [9]. In India, Mundle and colleagues compared the manually administered IV loading  
107 dose followed by maintenance therapy given by IM route of administration via a syringe, to a  
108 loading dose and maintenance therapy given through IV infusion administered by a Springfusor  
109 device. Though there were no difference in maternal and neonatal morbidity, the Springfusor had  
110 few side effects[9]. Later, Easterling et al compared the Springfusor administration of continuous  
111 IV infusion of magnesium sulphate and 2 hourly IV boluses, the clinical findings were not  
112 different in the two groups[8]. Earlier in 1994, Freebairn et al in Australia compared the  
113 Spingfusor infusion device to intermittent boluses on administration of muscle relaxant. They  
114 were able to show that Springfusor provided a more constant level of paralysis compared to  
115 intermittent bolus administration [10]. The objective of this study was to assess the acceptability  
116 and safety of Springfusor pump for intravenous delivery of magnesium sulphate for the treatment  
117 of preeclampsia and eclampsia.

## 118 **Methods**

119 The trial protocol is submitted as a supplementary file (S2). The study was randomized open  
120 label clinical trial conducted at Kawempe national referral and teaching hospital in Kampala  
121 district Uganda. The hospital is a government public facility and its Maternal Fetal Unit admits  
122 and delivers approximately 2100 pregnant women per month. From the facility records, 7% of  
123 the admissions are preeclamptic/eclamptic women. The women with preeclampsia and eclampsia

124 are managed by cadres of health workers ranging from senior consultant obstetricians to medical  
125 officers, while the midwives administer the medication and nursing care.

126 The study included women with age of 15 years and above, with a pregnancy of 20+ weeks of  
127 gestation or had childbirth within 24 hours, presenting with preeclampsia and eclampsia i.e.,  
128 have a raised blood pressure (systolic of  $\geq 140$  mmHg and/or diastolic  $\geq 90$  mmHg), proteinuria  
129  $\geq 1+$ . We excluded women who had received MgSO<sub>4</sub> 24 hours prior to admission, or had known  
130 allergy to MgSO<sub>4</sub> and known elevated serum creatinine ( $>1.2$  mg/dl) before enrolment.

131 Intervention: Women in the intervention arm (Springfusor® group) had the loading and  
132 maintenance therapy of MgSO<sub>4</sub> using IV infusion administered using a Springfusor® infusion  
133 pump. The loading dose was 4 gm of 50% MgSO<sub>4</sub> in 10 ml syringe administered over 20 mins.  
134 The infusion rate was determined by the flow control tubing calibrated to deliver 10 ml of saline  
135 over 5 mins (this system was demonstrated to deliver 4gm of 50% MgSO<sub>4</sub> in 20 mins)[9]. The  
136 maintenance dose of 4 gm of 50% MgSO<sub>4</sub> in 8 ml was administered over 4 hours and infusion  
137 rate was determined by a second flow control tubing calibrated to deliver 10 ml of saline over 60  
138 mins (this system was demonstrated to deliver 4gm of 50% MgSO<sub>4</sub> in 4 hours)[9]. The 4-gm  
139 dose of MgSO<sub>4</sub> was repeated every 4 hours for 24 hours.

140 Women in the control arm (standard of care) had MgSO<sub>4</sub> administered according to the standard  
141 hospital practice. The loading dose of 4 gm of 20% MgSO<sub>4</sub> in 20 ml syringe was administered  
142 using an IV infusion over 15-20 mins. This was immediately followed by IM injection of 10 gm  
143 of 50% MgSO<sub>4</sub> mixed with 1 ml of lignocaine into the gluteal muscles (5 gm on each buttock).  
144 This was followed by maintenance dose of 5 gm IM injection, administered every 4 hourly for  
145 24 hours.

146 **Study procedure:**

147 Between March and September 2019, women admitted at Kawempe hospital maternal fetal unit  
148 were screened and enrolled into the study if they meet the inclusion criteria. The study team  
149 obtained a written informed consent from the participant or from the relative if the mother was  
150 eclamptic. Those with eclampsia provided individual written consent when they regained their  
151 consciousness. Both arms received the care as per national guidelines which included  
152 management of high blood pressure using antihypertensives, laboratory investigations (urine  
153 analysis, complete blood count, renal function tests and liver function tests),  
154 prevention/treatment of fits and delivery as planned by the attending physicians. Upon  
155 enrolment, study participants were randomized to intervention or standard of care arms. The  
156 prevention and treatment of fits were started as per hospital guidelines. The time it took to  
157 administer the loading and maintenance doses in both arms were measured in mins by study  
158 nurse using a stop clock. The time was measured from the loading of the  $MgSO_4$  into syringe to  
159 completion of administration of the medicine in the syringe. For this paper we report the duration  
160 in mins it took to administer the loading dose and the second maintenance dose.

161 The study participants' respiratory rates were monitored by the study midwives every 5 mins  
162 during the loading dose for 30 mins and hourly during the 24 hours maintenance dose  
163 administration. In addition, urine output and tendon reflexes were monitored hourly and  
164 documented in the source documents. The side effects of  $MgSO_4$  like nausea, vomiting, flushing  
165 of the skin, muscle weakness, confusion and drowsiness were reported 4 hourly and were  
166 captured in questionnaire. The study participants were followed till discharge from the hospital  
167 and pregnancy outcomes were extracted from the participants' records or charts.



168 The primary outcome was acceptability of the method of MgSO<sub>4</sub> administration assessed using  
169 Likert scale (1-5; 1: acceptable and 5: unacceptable), administered after the last maintenance  
170 dose. The method of MgSO<sub>4</sub> administration was regarded acceptable if participant rated it 1 or 2,  
171 and was unacceptable if participant scored it 3 or more. The secondary outcomes were 1) the  
172 level of pain experienced during administration of MgSO<sub>4</sub> and this was assessed using a visual  
173 analogue scale 1-7. The least (one) representing no pain and maximum (7) representing the worst  
174 pain imaginable, 2) proportion of complications in two arms measure as proportion of  
175 preeclamptic women who developed any one of the following; MgSO<sub>4</sub> toxicity, abnormal liver  
176 and renal function test as reported by the laboratory report, an infection at the injection as  
177 reported by the clinician or a maternal deaths; 3) discontinuation rate was assessed as study  
178 participants who did not complete the recommended doses of MgSO<sub>4</sub> in 24 hour period.  
179 Participants who discontinued the method of administration by choice, due to side effects or by  
180 health workers decision were counted in each group, and; 4) reliability of Springfusor® pump in  
181 the delivery of MgSO<sub>4</sub> measured as time taken by the device to deliver the MgSO<sub>4</sub> as per the  
182 clinical recommendations.

### 183 **Sample size, randomisation and statistical analysis**

184 Based on the 31% acceptability of MgSO<sub>4</sub> administration using the Pritchard regimen (IM  
185 maintenance) in the Mundle et al trial[9], we calculated that we needed a sample size of 219  
186 participants in each arm to give 90% power to detect 50% difference between the Springfusor  
187 arm and standard of care, with alpha of 0.05. With approximately 10% non-response, we needed  
188 241 women in each arm.

189 Randomization was performed by a biostatistician not involved in the clinical trial who  
190 developed the allocation sequence using an online computer random number generator in block

191 sizes of 4 and 6. The allocation sequence was concealed from the research team enrolling and  
192 screening participant in serially numbered sealed opaque envelopes (concealed allocation)  
193 containing the randomization group. After the research nurse had obtained the consent, she  
194 opened the next envelope to determine the group assignment only after the participant is  
195 enrolled, completed all the baseline assessment and it is time to allocate the intervention.  
196 Because of the nature of the study, it was difficult to blind the implementation of the allocation  
197 and measurement of the outcome.

198 Descriptive statistics were used to summarize baseline characteristics of study participants and  
199 assess if randomization was successful. Acceptability and safety data were evaluated using  
200 intention-to-treat (ITT) analysis. The primary outcome (acceptability of administration of  
201 MgSO<sub>4</sub> using Springfusor) was assessed using a Likert scale ranging from one (very acceptable)  
202 to five (very unacceptable). The method of MgSO<sub>4</sub> administration was regarded acceptable if  
203 participant rated 1 or 2 on the Likert scale. It is not acceptable if the rating was three and above.  
204 Women who discontinue the method of administration by choice or due to side effects were  
205 considered in group of the unacceptable. The acceptability was compared in the two groups  
206 using chi-square. Secondary outcomes (complications of preeclampsia and its management and  
207 discontinuation rates) were compared using chi-square. While the level of pain was compared  
208 using means. The reliability of the Springfusor to administer MgSO<sub>4</sub> in the prescribed time was  
209 assessed for the loading period and the maintenance period.

## 210 **Ethical considerations**

211 Approval for this research was provided by the Makerere University School of Medicine Research and  
212 Ethics Committee (REC Ref 2018- 015) and the Uganda National Council for Science and Technology  
213 (HS 2365). Study participants provided written informed consent. The trial was registered with Pan

214 African Clinical Trails PACTR201712002887266. The results are reported in accordance with the  
215 CONSORT statement for randomized control trials[11] and checklist is provided as supporting file

216

## 217 **Results**

218 Participants flow: Eligible participants were recruited from March to August 2019.

219 Approximately, ten thousand (9828) women admitted at the maternal fetal unit of Kawempe  
220 national referral hospital during the study period were screened for eligibility ([Fig. 1](#)). A total of  
221 496 eligible participants were randomized to intervention or standard of care. The loss-to-follow-  
222 up was similar in both arms. The 5 referrals to other facilities were for renal consultations to rule  
223 out possible acute kidney injury and Mulago Women Specialized Hospital to decongested  
224 Kawempe hospital when it was overloaded with patients.

## 225 **Baseline characteristics**

226 Table 1 shows the baseline characteristics of the women enrolled in the control and interventions  
227 arms. The baseline data established that randomization of the two arms were similar for almost  
228 all variables except for presenting as a postpartum and multiple pregnancy. The differences in  
229 the 2 variables were not statistically significant. More than two thirds of participants were  
230 referrals from lower facilities

231 Table 1 Demographic and clinical characteristics of the study participants

<b>Particulars</b>	<b>Standard of care (Pritchard) arm N=248 (%)</b>	<b>Springfusor arm N=248 (%)</b>
Age in years		
Mean (SD)	27.2 (5.5)	26.5 (5.6)
Range	17 - 42	16 -45
Gravidity n (%)		
1	83 (33.5)	94 (37.9)
2	41 (16.7)	39 (15.7)

3	37 (15.1)	44 (17.7)
4	30 (12.1)	29 (12.0)
5+	44 (18.0)	35 (11.1)
Average gravida; mean (SD)	2.7 (1.7)	2.5 (1.7)
Enrolled postpartum (given birth) n (%)	13 (5.3)	7 (2.8)
Gestation age at enrollment n (%)		
20-33	74 (29.8)	61 (24.6)
34-37	78 (31.5)	94 (37.9)
38+	79 (31.9)	79 (31.9)
Unknown/missing/postpartum	17 (6.9)	14 (5.6)
Average gestation age in weeks at enrolment; mean (SD)	34.4 (4.8)	34.8 (4.6)
Gestation age range (weeks)	20 - 43	20 - 43
Number of ANC visits (%)		
None	10 (4.0)	8 (3.2)
1-3	145 (58.5)	142 (57.3)
4+	93 (37.5)	98 (39.5)
Average number of ANC visits; mean (SD)	3.0 (1.3)	3.2 (1.3)
Multiple pregnancy* (%)	21 (8.5)	14 (5.8)
Admitted as n (%)		
Referral in	179 (72.2)	172 (70.1)
Self-referral (Walk in)	23 (9.3)	34 (13.7)
Antenatal clinic at study site	46 (18.5)	42 (16.9)
Systolic BP at enrolment mmHg		
Mean (SD)	168.8 (22.4)	167.0 (21.0)
Range	126 - 237	130 -270
≥160 mmHg (%)	145 (58.5)	151 (60.9)
Diastolic BP at enrolment mmHg		
Mean	111.5 (14.6)	112 (13.2)
Range	78 - 173	90 -162
≥110 mmHg (%)	129 (52.0)	142 (57.3)
Enrolled as Eclamptic (%)	14 (5.6)	11 (4.4)

232

233 Table 2 shows the laboratory parameters of the study participants enrolled into the control and  
 234 intervention arms. The baseline laboratory parameters were similar in the two with the exception  
 235 of low level of platelets and elevated serum creatinine in the intervention arm.

236 Table 2. Laboratory characteristics of the participants enrolled into the study

Particulars	Standard of care N=248 (%)	Springfusor n=248 (%)
Low platelets (<100x10 <sup>3</sup> /μmoll)	20 (8.1)	29 (11.7)
Elevated alanine transaminase (>31μmol/L)	46 (18.5)	40 (16.1)
Elevated aspartate transaminase (>32μmol/L)	70 (28.2)	69 (27.8)
Raised bilirubin (>3.4μmol/L)	87 (35.1)	80 (32.2)
Elevated serum creatinine (≥1.2mg/dL)*	20 (8.1)	38 (15.3)

237 \*Almost all the results were available for the attending physicians after the prevention and  
 238 treatment of fits with magnesium sulphate was initiated or completed. None of the participants  
 239 with elevated serum creatinine was excluded from the study.

240 The duration of MgSO<sub>4</sub> administration of loading dose was longer in the standard of care than in  
 241 Springfusor arm (table 3). Few women in both groups discontinued MgSO<sub>4</sub> (did not complete the  
 242 recommended 24-hour doses) and the rates were similar (5.3% vs 5.0% p=0.862).

243 Table 3. Drug administration and pain score registered by study participants

Particulars	Standard of care arm	Springfusor arm	pvalue
Average duration in mins of loading dose magnesium administration (sd)	25.8 (8.3)	21.1 (5.8)	P<0.001
Duration of administering the 2nd Maintenance (2 <sup>nd</sup> 4 hrs) in mins (sd)	2.8 (3.5)	236.3 (40.2)	N/A*
Discontinued MgSO <sub>4</sub> administration before 24 hours (%)	13 (5.3)	12 (5.0)	P=0.862
Reasons for discontinuation of MgSO <sub>4</sub>			
Doctor's advice	7	7	
Patients request	4	4	
Referred to another facility before completion	2	1	
Pain score after administration of MgSO <sub>4</sub> : 1(minimal), 7 (worst)			
1	11 (4.5)	71 (29.3)	
2	31 (12.6)	97 (40.1)	
3	48 (19.5)	38 (15.7)	
4	42 (17.1)	6 (2.5)	
5	55 (22.4)	14 (5.8)	
6	28 (11.4)	5 (2.1)	
7	21 (8.5)	4 (1.7)	
missing	10 (4.1)	7 (2.9)	

244 \*Not provided statistic, will be misinterpreted and provides no meaning.

245 As shown in table 4, almost all women in the intervention group found Springfusor  
 246 administration of MgSO<sub>4</sub> acceptable (95%) compared to the standard of care (70%) and this was  
 247 a statistically significant (chi 49.7 p<0.001). The women in the standard of care arm had a higher  
 248 mean pain score than the intervention arm (standard of care: 4.1(±1.6); Springfusor: 2.2(±1.3)  
 249 mean difference 1.9, CI: 1.8-3.0 p<0.001). More women in the intervention arm would  
 250 recommend Springfusor method of administration of MgSO<sub>4</sub> to a friend compared to standard of  
 251 care (96% vs 61%). Similarly, almost all women in the intervention arm would use the  
 252 Springfusor for magnesium administration when they have raised blood pressure in the next  
 253 pregnancy compared to control arm who would Pritchard method (96.5% vs 66%).

254 Table 4. Acceptability of MgSO<sub>4</sub> administration using Springfusor compared to standard of care

Outcome	Control group (SOC) N=236(%)	Intervention group (Springfusor) N=235(%)		p-value
<b>Primary outcome</b>				
Acceptable ≤2 score on Likert scale (%)	166 (70.3)	224 (95.3)		<0.001
<b>Secondary outcomes</b>				
Discontinuation; Not completed the 24 hrs (%)	13 (5.5)	12 (5.1)		0.862
Mean pain score during administration (sd)	4.1 (1.6)	2.2 (1.3)	Mean diff 1.9 (CI: 1.8 – 3.0)	<0.001
Would recommend method of administration of MgSO <sub>4</sub> to friend (%)	145 (61.4)	226 (96.2)		<0.001
Would use it in future she got raised BP in next pregnancy	155 (65.7)	225 (95.7)		<0.001

255

256 The side effects like flushes, nausea, vomiting, drowsiness, and diplopia were more in the  
 257 standard of care than in springfusor (table 5). However, the adverse events like respiratory  
 258 depression, depressed patellar reflex and cardiac arrest were very few and were comparable in  
 259 the two arms

260 Table 5. Adverse and Side effects experienced during the 24 hours of drug administration

Particulars	Total (N=487)	Standard of care (n=245)	Springfusor (n= 242)
Flushes	373 (76.8)	201 (80.0)	172 (71.4)
Nausea	120 (24.7)	70 (28.6)	50 (20.8)
Vomiting	56 (11.5)	33 (13.5)	23 (9.5)
Headache	107 (22.0)	52 (21.2)	55 (22.8)
Drowsiness	164 (33.7)	97 (39.6)	67 (27.8)
Diplopia	16 (3.3)	7 (2.9)	9 (3.7)
Burning/warm sensation at site of injection	136 (28.0)	68 (27.8)	68 (28.2)
Respiratory depression <16 breath/min	2 (0.5)	1 (0.5)	1 (0.5)
Depressed patellar reflexes	1 (0.5)	1 (0.5)	0 (0.0)
Cardiac arrest	2 (0.5)	1 (0.5)	1 (0.5)

261  
 262 Approximately 6% of the participants were discharged from the hospital while still pregnant  
 263 after the blood pressures were controlled (table 6). Though outcomes of pregnancy were  
 264 comparable in both arms, more women were delivered by caesarean section in the Springfusor  
 265 arm than SOC. There were approximately 3% of the participants were referred to renal physician  
 266 for specialized care (including dialysis) and follow up. Unfortunately, there were 5 maternal  
 267 deaths in the whole study.

268 Table 6. Pregnancy outcome of the study participants

Characteristics	Total (%)	Standard of care (%)	Intervention (%)
Discharged while still pregnant	28 (5.8)	18 (7.4)	10 (4.1)
Mode of delivery (n=458)			
Caesarean	201 (43.9)	80 (35.2)	121 (52.4)
Vaginal	257 (56.1)	147 (64.8)	110 (47.6)
Outcome of the delivery (fetus)n=488			
Alive	398 (81.6)	195 (80.9)	203 (82.5)
Still births	84 (17.2)	43 (17.8)	41 (16.7)
missing	6 (1.2)	3 (1.2)	3 (1.2)
Weight of the baby			
<2500 gm	244 (50.5)	126 (52.3)	118 (48.8)
≥2500 gm	239 (49.5)	115 (47.7)	124 (51.2)
Referred to Nephrology hospital for further renal care n=487	14 (2.9)	8 (3.3)	6 (2.5)
Maternal death	5 (1.0)	3 (1.2)	2 (0.8)
No convulsion after loading dose	0	0	0

269

## 270 Discussion

271 The definitive treatment of preeclampsia is the delivery of the fetus and placenta. However,  
272 before and after delivery of the baby and placenta, the goal of management is to control the  
273 blood pressure to normal range and minimize the development of complications like eclampsia.  
274 MgSO<sub>4</sub> is the anticonvulsant for eclampsia prophylaxis and treatment[12]. MgSO<sub>4</sub> therapy could  
275 be given by continuous IV infusion (Zuspan) [6] or by administering an IV bolus and IM doses  
276 for the loading dose followed by IM injections every 4 hours (Pritchard) used [13]. In low  
277 resource settings due to unavailability of the electronic pumps, the Pritchard regimen is the  
278 standard of care. The loading dose of 4gm of MgSO<sub>4</sub> is often delivered via an IV-push over 15-  
279 20 mins. This process is challenging for the provider and difficult in a busy ward, and is  
280 associated with inconsistent flow rates. If administered faster than the recommended 15-20 mins,  
281 the IV-push may lead to increased pain, nausea, vomiting and flushing. Meanwhile the repeated



282 IM injections that follow the loading dose are associated with pain, hot flushes, somnolence, and  
283 sometimes abscess formation at the site of injection.

284 We assessed the acceptability and safety of Springfusor pump for intravenous delivery of MgSO<sub>4</sub>  
285 for prophylaxis and treatment of eclampsia among women admitted at Kawempe national  
286 referral hospital. Acceptability of intravenous administration of MgSO<sub>4</sub> using Springfusor was  
287 higher compared to Pritchard regimen (standard of care). The level of acceptability of  
288 intravenous administration of MgSO<sub>4</sub> using Springfusor was comparable to study by Mundle et  
289 al in India that found that it was 97%[9]. The low acceptability associated with standard of care  
290 is most likely due to pain that follows IM injection. Literature shows that the anxiety and fear  
291 associated with pain following IM injection reduces the acceptability of treatment to the patients  
292 [14, 15]. With the four-hourly frequency of IM injection of MgSO<sub>4</sub> for prophylaxis and treatment  
293 of preeclampsia and eclampsia in standard of care, injection site pain is an important concern and  
294 local guidelines propose an addition of local anesthetic agent (Lignocaine) into the drug. Despite  
295 the addition of 1 ml of lignocaine into every IM injection of MgSO<sub>4</sub>, our study findings showed  
296 that participants on the standard of care experienced higher pain score than women who received  
297 drug through intravenous administered through the Springfusor pump.

298 Majority (96%) of the participants in intervention arm responded that they would recommend IV  
299 magnesium sulfate administered using Springfusor to other patients compared to standard of care  
300 (61%). In addition, almost all participants in intervention arm (97%) compared to two thirds  
301 (66%) in standard of care would use MgSO<sub>4</sub> administered using Springfusor in future pregnancy  
302 if she gets preeclampsia. Literature reports that, when the safety and efficacy of two injection  
303 routes are equivalent, health care providers should consider more about patient preference  
304 because it will ensure optimal treatment adherence and ultimately improve patients experience or

305 satisfaction[16, 17]. In our study findings showed that no women developed a fit after enrolment,  
306 indicating that both routes and dosing prevented and control the convulsions adequately.

307 Over all, the discontinuation rate was low (5.1%) and there was no difference in the two arms.

308 The low rates of discontinuation could be because this assessment was among participants that

309 participated in research study environment which has ample opportunities for questions,

310 comments, and explanation of the process. In the real world, it is unlikely that this level of

311 support will be available. Slightly more than half (56%) of the discontinuation were due to

312 physician on duty recommendation. The other reasons for discontinuation were due to

313 participants request, and three patients referred to seek treatment in another facility.

314 The Springfusor® pump and flow control tube (FCT) is an encouraging alternative to repeated

315 IM administration of MgSO<sub>4</sub>, designed to make simpler, the continuous IV infusions. It does not

316 require electricity and it is reusable. The Springfusor is powered by the potential energy stored

317 within a spring at the heart of the device ([Fig. 2](#)) suitable for low resource settings. The FCT

318 exist in a variety of flow rates which enables the user to attain the desired output for exact IV

319 delivery needs. For this study we used two varieties of FCT as shown in the figure 2; the loading

320 dose and maintenance dose. The Springfusor syringe infusion pump is a low-cost technology that

321 requires only minimal training to load and operate. Being lightweight, and with a neck strap, it

322 does not limit the mobility of the patient ([Fig. 3](#)).

323 Thes study had some limitations. Firstly, the delay in accessing the laboratory work of the

324 participants, resulted in some participants who should be excluded based on serum creatinine,

325 enrolled into the study. The standard of care at the facility does not wait for laboratory results

326 before starting MgSO<sub>4</sub> prophylaxis. We operated within the hospital guidelines. Fortunately, no

327 participant experienced MgSO<sub>4</sub> toxicity. Secondly, we could not blind the study to the

328 participants and providers and might have influenced the reporting of the outcomes. The nature  
329 of the study could not enable blinding of the study.

## 330 Conclusion

331 Acceptance of prescribed therapy is key for adherences and to clinical outcomes, and the effect is  
332 particularly critical for treatment that require repeated injections like MgSO<sub>4</sub> for preeclampsia  
333 and eclampsia. Pain associated with intramuscular injection (standard of care) was less with the  
334 intravenous infusion (Springfusor®) than with intramuscular administration. In addition, the  
335 intravenous administration was preferred to standard of care with women endorsing a greater  
336 likelihood to use it in next pregnancy or recommend it to a friend.

## 337 Acknowledgement


338 The authors are grateful to Kawempe National Referral Hospital administration and staff for support in  
339 study implementation, data collectors for the great work done and the participants who gave in their time  
340 to participate in the study.

## 341 References

- 342 1. Report of the National High Blood Pressure Education Program Working Group on High Blood  
343 Pressure in Pregnancy. American journal of obstetrics and gynecology. 2000;183(1):S1-S22. PubMed  
344 PMID: 10920346.
- 345 2. Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in perinatology.  
346 2009;33(3):130-7. doi: 10.1053/j.semperi.2009.02.010. PubMed PMID: 19464502.
- 347 3. Mousa A, Mandili RL, Aljahdali M, Gari S, Khaimi S, Alahdal S, et al. Maternal and Fetal Outcomes  
348 of Preeclampsia With and Without Severe Features in King Abdulaziz University Hospital, Jeddah, Saudi  
349 Arabia: A Retrospective Study. Cureus. 2022;14(11):e31013. Epub 2022/12/08. doi:  
350 10.7759/cureus.31013. PubMed PMID: 36475125; PubMed Central PMCID: PMCPCMC9717715.
- 351 4. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal  
352 death: a WHO systematic analysis. The Lancet Global health. 2014;2(6):e323-33. Epub 2014/08/12. doi:  
353 10.1016/S2214-109X(14)70227-X. PubMed PMID: 25103301.
- 354 5. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. WHO  
355 Guidelines Approved by the Guidelines Review Committee. Geneva2011.
- 356 6. Zuspan FP. Problems encountered in the treatment of pregnancy-induced hypertension. A point  
357 of view. American journal of obstetrics and gynecology. 1978;131(6):591-7. PubMed PMID: 686045.
- 358 7. Go Medicals Industries Pty Ltd. Innovative Products to improve common medical procedures.  
359 <http://www.gomedical.com.au/products/infusion/springfusor-fct> Accessed September 25, 2017.


- 360 8. Easterling T, Hebert M, Bracken H, Darwish E, Ramadan MC, Shaarawy S, et al. A randomized  
361 trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with  
362 serial intravenous boluses versus a continuous intravenous infusion. *BMC pregnancy and childbirth*.  
363 2018;18(1):290. Epub 2018/07/07. doi: 10.1186/s12884-018-1919-6. PubMed PMID: 29976161; PubMed  
364 Central PMCID: PMC6034206.
- 365 9. Mundle S, Regi A, Easterling T, Biswas B, Bracken H, Khedekar V, et al. Treatment approaches for  
366 preeclampsia in low-resource settings: A randomized trial of the Springfusor pump for delivery of  
367 magnesium sulfate. *Pregnancy hypertension*. 2012;2(1):32-8. doi: 10.1016/j.preghy.2011.09.002.  
368 PubMed PMID: 26104987.
- 369 10. Freebairn R, Joynt GM, Lipman J, Bothma PA. A double-blind comparison of vecuronium  
370 administered by the Springfusor infusion device to vecuronium by intermittent bolus injection in  
371 critically ill adult patients. *Anaesthesia and intensive care*. 1994;22(5):580-5. PubMed PMID: 7818063.
- 372 11. Murphy JF. Consort 2010 statement on randomised controlled trials. *Ir Med J*. 2010;103(5):132.  
373 Epub 2010/07/30. PubMed PMID: 20666080.
- 374 12. Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for  
375 eclampsia. *The Cochrane database of systematic reviews*. 2010;(12):CD000127. doi:  
376 10.1002/14651858.CD000127.pub2. PubMed PMID: 21154341.
- 377 13. Pritchard JA. The use of the magnesium ion in the management of eclamptogenic toxemias.  
378 *Surgery, gynecology & obstetrics*. 1955;100(2):131-40. PubMed PMID: 13238166.
- 379 14. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations.  
380 *The American journal of tropical medicine and hygiene*. 2003;68 3:341-4.
- 381 15. Friedmann PD, Mello D, Lonergan S, Bourgault C, O'Toole TP. Aversion to injection limits  
382 acceptability of extended-release naltrexone among homeless, alcohol-dependent patients. *Subst Abuse*.  
383 2013;34(2):94-6. Epub 2013/04/13. doi: 10.1080/08897077.2012.763083. PubMed PMID: 23577900;  
384 PubMed Central PMCID: PMC4394196.
- 385 16. Gandell DL, Bienen EJ, Gudeman J. Mode of injection and treatment adherence: results of a  
386 survey characterizing the perspectives of health care providers and US women 18-45 years old. *Patient*  
387 *Prefer Adherence*. 2019;13:351-61. Epub 2019/03/14. doi: 10.2147/PPA.S187120. PubMed PMID:  
388 30863023; PubMed Central PMCID: PMC6391128.
- 389 17. Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, et al. The optimal choice of medication  
390 administration route regarding intravenous, intramuscular, and subcutaneous injection. *Patient Prefer*  
391 *Adherence*. 2015;9:923-42. Epub 2015/07/15. doi: 10.2147/PPA.S87271. PubMed PMID: 26170642;  
392 PubMed Central PMCID: PMC4494621.

393



medRxiv preprint doi: <https://doi.org/10.1101/2023.05.16.23290038>; this version posted May 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Fig. 1. Consort diagram showing the participants flow



medRxiv preprint doi: <https://doi.org/10.1101/2023.05.16.23290038>; this version posted May 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

**Fig. 2 The Springfusor pump with a 10 mls syringe, flow control tubing (FCT) for administration of the loading and maintenance doses of MgSO<sub>4</sub>**

Fig. 2 Springfusor pump & FCT



*Fig. 3 Showing participant with Springfusor pump with magnesium sulphate administered through a canula. The neck suspension string enables participants mobility without fear of dislodging the canula.*

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.16.23290038>; this version posted May 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.